Diurnal Group PLC Hardman & Co Life Sciences Investor Forum
17 Septiembre 2021 - 01:00AM
RNS Non-Regulatory
TIDMDNL
Diurnal Group PLC
17 September 2021
17 September 2021
Diurnal Group plc
("Diurnal" or the "Company")
Diurnal to present at Hardman & Co Life Sciences Investor
Forum
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, will be presenting at the Hardman & Co Life Sciences
Investor Forum on Thursday 23 September 2021. The webinar event
will begin at 17:00 BST and investors can register to attend here:
https://hardman-co.com/p/49CL-HU2/join-our-webinar
Martin Whitaker, Chief Executive Officer of Diurnal, will be
presenting an overview of the Company and will be available to take
questions during the event.
For further information, please visit www.diurnal.co.uk or
contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886
and Sole Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: Rupert Dearden
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Alex Davis
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty
pharmaceutical company dedicated to developing hormone therapeutics
to aid lifelong treatment for rare and chronic endocrine
conditions, including congenital adrenal hyperplasia, adrenal
insufficiency, hypogonadism and hypothyroidism. Its expertise and
innovative research activities focus on circadian-based
endocrinology to yield novel product candidates in the rare and
chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUPGBUPGGQQ
(END) Dow Jones Newswires
September 17, 2021 02:00 ET (06:00 GMT)
Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024